Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Denali Therapeutics (DNLI) Treasury Shares (2017 - 2025)

Denali Therapeutics (DNLI) has disclosed Treasury Shares for 9 consecutive years, with $5.2 million as the latest value for Q3 2025.

  • On a quarterly basis, Treasury Shares rose 29.62% to $5.2 million in Q3 2025 year-over-year; TTM through Sep 2025 was $5.2 million, a 29.62% increase, with the full-year FY2024 number at $4.1 million, up 13.57% from a year prior.
  • Treasury Shares was $5.2 million for Q3 2025 at Denali Therapeutics, up from $5.1 million in the prior quarter.
  • In the past five years, Treasury Shares ranged from a high of $5.2 million in Q3 2025 to a low of $2.6 million in Q3 2021.
  • A 5-year average of $3.7 million and a median of $3.7 million in 2023 define the central range for Treasury Shares.
  • Peak YoY movement for Treasury Shares: skyrocketed 64.78% in 2021, then increased 7.43% in 2024.
  • Denali Therapeutics' Treasury Shares stood at $2.6 million in 2021, then grew by 26.64% to $3.3 million in 2022, then increased by 9.14% to $3.6 million in 2023, then rose by 13.57% to $4.1 million in 2024, then increased by 25.4% to $5.2 million in 2025.
  • Per Business Quant, the three most recent readings for DNLI's Treasury Shares are $5.2 million (Q3 2025), $5.1 million (Q2 2025), and $4.8 million (Q1 2025).